Qiagen reported healthy numbers with Q4 16 sales coming slightly below but earnings marginally ahead of the street’s expectations. On a CER basis, sales went up by 8% (in line with management’s expectations), including 5% organic and 3% acquisitive growth (Mo Bio and Exiqon), supported by both consumables (8% CER, c.86% of sales) and instruments (6% CER, c.14 of sales). However, a 3% currency headwind truncated the reported sales progression (up 5% to $366.5m). On a segmental leve
02 May 2017
Healthy Q4, growth inflection seems realistic on accelerated portfolio transformation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy Q4, growth inflection seems realistic on accelerated portfolio transformation
Qiagen reported healthy numbers with Q4 16 sales coming slightly below but earnings marginally ahead of the street’s expectations. On a CER basis, sales went up by 8% (in line with management’s expectations), including 5% organic and 3% acquisitive growth (Mo Bio and Exiqon), supported by both consumables (8% CER, c.86% of sales) and instruments (6% CER, c.14 of sales). However, a 3% currency headwind truncated the reported sales progression (up 5% to $366.5m). On a segmental leve